P&G withdraws Intrinsa NDA
Executive Summary
Procter & Gamble withdraws NDA for female testosterone patch Intrinsa, but plans to resubmit the application for the hypoactive sexual desire disorder treatment with additional data from trials in naturally menopausal women. The trials are "nearly complete," the company said. At its Dec. 2 meeting, the Reproductive Health Drugs Advisory Committee agreed that additional safety data is needed because of the potential for broad off-label use (1"The Pink Sheet" Dec. 6, 2004, p. 18). The company was seeking an indication for use in surgically menopausal women...